Evaluation of human immunodeficiency virus type 1-infected chinese patients treated with highly active antiretroviral therapy for two years

Viral Immunology

Volumn 20, Issue 1, 2007, Pages 180-187

  Zhou, Hua Ying ^a   Zheng, Yu Huang ^a   Zhang, Chun Ying ^a   Chen, Jun ^a   He, Yan ^a   Ding, Pei Pei ^a   Li, Hui ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CD38 ANTIGEN; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; VITAMIN; ZIDOVUDINE;

ABDOMINAL FULLNESS; ABDOMINAL PAIN; ADULT; ALOPECIA; AMYLASE BLOOD LEVEL; APPETITE DISORDER; ARTICLE; BLOATING; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CHINA; CHINESE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVALUATION; FACE DISORDER; FACIAL ZOSTER; FATIGUE; FEMALE; FEVER; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEADACHE; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LACTIC ACIDOSIS; LIMB PAIN; LUNG INFECTION; MALE; MEMORY CELL; NAUSEA; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; RASH; SIDE EFFECT; TOXIC HEPATITIS; VIRUS LOAD; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; DIDANOSINE; FEMALE; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEVIRAPINE; STAVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247260001     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.0047     Document Type: Article

References (24)

1. Louie M, and Markowitz M: Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: A pathogenesis-based perspective. Antiviral Res 2002;55:15-25.
2. Zhou HY, Zheng YH, Zhang CY, et al.: A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy. Chin Med J (Engl) 2005;118:609-611.
3. Li L, Wei FL, Mei S, et al.: Virological and immunological outcomes in HIV-1 infected Chinese patients treated with a combination of efavirenz and indinavir for 48 weeks. Chin Med J (Engl) 2004;117:347-352.
4. Zhou HY, Zheng YH, Yang X, et al.: A Twenty four week clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy. J Chin Physician 2003;5:1592-1595.
5. Amin J, Moore A, Carr A, et al.: Combined analysis of two year follow-up two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials 2003;4:252-261.
6. Valdez H, Connick E, Smith KY, et al.: Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859-1866.
7. Dybul M, Fauci AS, Bartlett JG, et al.: Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002;137:381-433.
8. Ungsedhapand C, Srasuebkul P, Cardiello P, et al.: Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection. J Acquir Immune Defic Syndr 2004;36:693-701.
9. Raffil F, Reliquet V, Ferrel V, et al.: The VIRGO Study: Nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1 infected adults. Antiviral Ther 2000;5:267-272.
10. French M, Amin J, Roth N, et al.: Randomized, open-table, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 study. HIV Clin Trials 2002;3: 177-185.
11. Katzenstein D: Adherence as a particular issue with protease inhibitors. J Assoc Nurses AIDS Care 1997;8(Suppl): 10-17.
12. Piroth L, Grappin M, Waldner A, et al.: Les arrêts pour intolérance des traitements par inhibiteurs de la protease du VIH-1: Etude longitudinale de 309 patients. Presse Med 1999;28:381-387.
13. AIDSinfo, U.S. Department of Health and Human Services: Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Available at http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL01282000010. pdf (accessed February 2006).
14. Murphy RL, Katlama C, and Johnson V: The Atlantic Study: A randomized open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 weeks data [abstract LB-22]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26-29, 1999.
15. Spruance SL, Pa via AT, Mellors JW, et al.: Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. Ann Intern Med 1997;126:355-363.
16. Deminie C, Bechtold C, Riccardi K, et al.: Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy. AIDS 1998;12:110-112.
17. Paredes R, Mocroft A, Kirk O, et al.: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA Study. Arch Intern Med 2000; 160:1123-1132.
18. Mocroft A, Gill MJ, Davidson W, and Phillips AN: Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 1998;12:2161-2167.
19. Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet 1999;353:863-868.
20. Mocroft A, Ruiz L, Reiss P, et al.: Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003;17:1741-1751
21. Gulick RM, Mellors JW, Havlir D, et al.: Three-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000;133:35-39.
22. Anthony KB, Yoder C, Metcalf JA, et al.: Incomplete CD4 T cell recovery in HIV-1 infection after 12 mo of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003;33:125-133.
23. Initio Co-ordinating Committee: An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: Design, rationale, and methods of the initial trial. Control Clin Trials 2001;22: 160-175.
24. Walker VA, Setzer B, and Venhoff N: Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002;16: 2165-2173.